Philipp Dohnke

Total Page:16

File Type:pdf, Size:1020Kb

Philipp Dohnke Philipp Dohnke Partner Corporate and M&A, Intellectual property Primary practice Corporate and M&A, Intellectual property 25/09/2021 Philipp Dohnke | Freshfields Bruckhaus Deringer About Philipp Dohnke <p><strong>Philipp is a member of our intellectual property and information technology team. </strong></p> <p>Since joining the firm, he has worked across many industries with a particular focus on life science and technologies. Philipp has broad expertise&nbsp;in complex, high-profile transactions, including large carve-out and asset deal projects. In addition, Philipp is experienced in drafting and negotiating complex commercial contracts.</p> <div> <p>He&nbsp;speaks German and English.</p> </div> Recent work <ul> <li>Apax and Warburg Pincus on their &euro;5,1bn acquisition of T-Mobile Netherlands</li> <li>Osram on the cave-out and sale of its Digital Systems business in North America to Acuity</li> <li>Thermo Fisher on its &euro;725m acquisition of the viral vector manufacturing business of Novasep (Belgium)</li> <li>AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals</li> <li>Charterhouse / Serb on the $800m acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific Corporation</li> <li>Novartis on its $5.2bn acquisition of pharmaceutical product Xiidra from Takeda/Shire</li> <li>Merck on its &euro;3.4bn carve-out und sale of its consumer health business to Procter &amp; Gamble</li> <li>Boehringer Ingelheim on its &euro;18bn business swap with Sanofi (Consumer Healthcare against Animal Health)</li> <li>Boehringer Ingelheim on its sale of rights in the pharmaceutical product Buscopan in Brazil to Hypera</li> <li>AstraZeneca / MedImmune on the acquisition of Definiens AG</li> <li>BioNTech on license deals and other collaborations in the field of mRNA products / individualized medicines (including with Pfizer, Genentech, Sanofi, Eli Lilly, Bayer Animal Health and Genmab)</li> <li>Advent International on the $1.9bn acquisition of Sanofi's generics business (Zentiva) and on the add-on acquisition of Alvogen's CEE business</li> <li>Bridgepoint on the acquisition of Pharmazell (manufacturer of active pharmaceutical ingredients)</li> <li>BC Partners on the &euro;2.6bn acquisition of CeramTec</li> <li>BC Partners on the acquisition of a majority stake in the Greek generics company Pharmathen</li> <li>Charterhouse / Cooper on the acquisition of a consumer health product portfolio from Sanofi</li> <li>Charterhouse / Serb on the acquisition of rights in a pharmaceutical product from a US biotech company</li> <li>CVC on the acquisition of a 50% stake in the pharmaceutical excipient manufacturer DFE Pharma from Fonterra (Joint Venture with FrieslandCampina)</li> <li>Qatar Investment Authority on an investment in the German biotech company CureVac</li> <li>Airbus on a joint venture with Bombardier regarding the aircraft program "C Series" (now "A220") and on the subsequent exit of Bombardier from the joint venture</li> <li>ABB on the carve-out and sale of its cable business to NKT</li> <li>Cinven/Hotelbeds on the acquisition of the Global Travel Distribution business from Kuoni</li> <li>Continental on the carve-out of its powertrain business ("Vitesco Technologies")</li> <li>Deutsche Bank on the carve-out and listing of its Asset Management business ("DWS")</li> <li>H.I.G. on the carve-out and acquisition of the European polyutherane "system house" business from Covestro</li> <li>Hellman &amp; Friedman on its &euro;2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck</li> </ul> Qualifications <p><strong>Education</strong></p> <ul> <li>Bucerius&nbsp;Law School, Hamburg, Germany,&nbsp;and&nbsp;Universit&eacute;25/09/2021 Philipp Dohnkede Paris| FreshfieldsI (Panth&eacute;on-Bruckhaus DeringerSorbonne), France&nbsp;(law)</li> Germany,&nbsp;and&nbsp;Universit&eacute; de Paris I (Panth&eacute;on-Sorbonne), France&nbsp;(law)</li> <li>Bucerius Law School, Hamburg, Germany&nbsp;(doctorate in law)</li> <li>Traineeship&nbsp;<em>(Referendariat)</em> at the Higher Regional Court of Hamburg, Germany</li> </ul> <p><strong>Professional memberships</strong></p> <ul> <li>German Association for the Protection of Intellectual Property</li> </ul> Contact Philipp [email protected] Hamburg Hohe Bleichen 7 20354 Hamburg T +49 40 36 90 60 F +49 40 36 90 61 55 25/09/2021 Philipp Dohnke | Freshfields Bruckhaus Deringer .
Recommended publications
  • Order 1 Purchase 2 Sale
    Form to be sent to: ORDER 1 BNP Paribas Securities Services AIRBUS GROUP Securities Department Les Grands Moulins de Pantin 9, rue du Débarcadère 93761 PANTIN CEDEX - FRANCE 2 PURCHASE SALE Tel. : +33 1 57 43 35 00 Fax: +33 1 57 43 01 54 Confirmation of the order dated .… / … / ……. made by phone 3 DD/MM/YYYY I the undersigned, Mr. / Mrs. / Ms. Last name First name(s) (Strike out as appropriate) (For legal persons: name of signatory) (For legal persons: first name of signatory) Company name SIREN (For legal persons) Date and place of at Phone birth (DD/MM/YYYY) (Mandatory) Account number Residing at Town Post code Country Tax address (if different only) give instructions to BNP Paribas Securities Services to transmit the following order: Stock AIRBUS GROUP ISIN Code NL0000235190 Number of shares (In words) (In figures) i1 Type of order At market price Limit order at ________________________ EUR (Specify the maximum purchase price or minimum sale price) Validity of order (maximum end of month): __________________________ Account details to be credited by wire: Name of the account holder Bank’s name Bank address Country Account currency In France: Code Banque Code Guichet Numéro de compte Clé RIB In other countries4: BIC Code IBAN ABA Code BSB Code Bank Code Branch Code Bank account For payment to an account using an IBAN / BIC code, please specify the payment currency in which the account is held: ……………………………… Documents to be supplied for a sale order 5: a Bank Account identity (RIB), Postal Account identity (RIP), Savings Account identity (RICE) or IBAN number for payment by transfer of the proceeds of the sale of shares, after deduction of brokerage fees, taxes and commissions.
    [Show full text]
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Airbus Corporate Jets Wins First Six ACJ Twotwenty Orders
    Airbus Corporate Jets wins first six ACJ TwoTwenty orders #ACJTwoTwenty #ACJ #COMLUX Toulouse, 6 October 2020 - Airbus Corporate Jets has won its first orders for the ACJ TwoTwenty totalling six aircraft following its launch. While Comlux has revealed an order for two aircraft, four further jets were ordered by undisclosed customers. Entry into service of the first ACJ TwoTwenty by Comlux Aviation is targeted for early 2023. The new ACJ TwoTwenty will feature a high end VIP cabin interior, supported by a flexible cabin catalogue, from which Comlux has selected the business and guest lounge as well as a private entertainment space and a private suite, including a bathroom. The cabin, set to “Reimagine your place in the sky...” will be equipped with large full lie flat seats, a US-king size bed, a standing rainshower, a humidifying system for well-being on board and leading edge connectivity. “We are proud to be the launch customer of the Airbus’ newest family member, the ACJ TwoTwenty and the selected partner to outfit the cabin in our completion center in Indianapolis. We have worked jointly with ACJ and shared our long experience in operating and completing all types of aircraft, to allow the new Bizjet to offer more comfort and the latest cabin innovations available in the industry, “ said Richard Gaona, Executive Chairman & CEO Comlux. “Thanks to the unique combination of intercontinental range, comfort, extra space and second-to-none economics, we are convinced the aircraft will be a winner in the business aviation market.” “We are honoured to see our longstanding client Comlux becoming the launch customer of our new ACJ TwoTwenty as well as our cabin completion partner on the programme, “ said Benoit Defforge, President ACJ.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • China Fully Committed to Debt Relief Plans Of
    BUSINESS CHINA DAILY HONG KONG EDITION Friday, October 30, 2020 Airbus to China fully start A350 deliveries committed to from debt relief Tianjin By ZHU WENQIAN [email protected] European aircraft manufac- turer Airbus said on Thursday plans of G20 that it is expected to deliver widebody A350 aircraft from its completion and delivery center Measures to ease burden of poor nations in Tianjin from the first quarter of next year. and boost sustainable development An aerial view shows volunteers posing amid the decorations at the National Exhibition and Con- The Airbus Tianjin widebody vention Center in Shanghai, the venue for the 3rd CIIE. GAO ERQIANG / CHINA DAILY completion and delivery center, By CHEN JIA global fiscal stimulus packages may the company’s first widebody [email protected] have achieved $12 trillion, and the completion and delivery center average deficit ratio is projected to outside Europe, is gradually China is implementing the debt increase by 9 percentage points Livestreaming to enhance value of CIIE shifting its work, including cabin relief plans promoted by the Group from last year. installation and aircraft paint- of 20 to help ease the debt burden of G20 finance ministers and cen- ing, to A350XWB. poor countries and achieve sustain- tral bank governors agreed to By HE WEI in Shanghai taining to say,” he said. fray, amid an army of online influ- “At the beginning, the delivery able development during the novel extend the Debt Service Suspen- [email protected] Apart from introducing new encers. Spectators are also antici- rate of A350 from Tianjin won’t coronavirus epidemic, a senior gov- sion Initiative by six months at a brands and products to the Chi- pated to converse virtually with be too fast, and we plan to gradu- ernment official said.
    [Show full text]
  • Weapon System of Choice 38 New Eurofighter Typhoon Aircraft for the Luftwaffe 2021 · EUROFIGHTER WORLD 2021 · EUROFIGHTER WORLD 3
    PROGRAMME NEWS & FEATURES JANUARY 2021 Chain Reaction Pilot Brief: Interoperability Eurofighter and FCAS Weapon System of Choice 38 new Eurofighter Typhoon aircraft for the Luftwaffe 2021 · EUROFIGHTER WORLD 2021 · EUROFIGHTER WORLD 3 Contents Programme News & Features January 2021 Welcome 4 Weapon System of Choice Airbus’ Head of Combat Aircraft Systems Kurt Rossner discusses the full implications of Germany’s decision to replace its existing Tranche 1 aircraft under the Quadriga programme. Cover: © Picture: images.art.design. GmbH, 12 Chain Reaction Lucas Westphal We speak to four businesses across Europe about the importance of the Eurofighter Typhoon programme for the Looking back, 2020 was a year few of us will ever The Eurofighter programme supports over 400 business- defence industry and the enriched technology capabilities forget. Because of the impact of the Covid-19 es across Europe, sustaining more than 100,000 jobs. it has helped bring about. pandemic we all faced huge professional and personal That’s why in this edition we shine the spotlight on some Eurofighter World is published by challenges. What stood out for me was the way every- of those supply chain businesses. Eurofighter Jagdflugzeug GmbH 18 Mission Future: Eurofighter and FCAS one involved in the Eurofighter project worked closer PR & Communications In the first of series of exclusive articles our experts exam- together than ever before to deliver. Elsewhere in the magazine we examine Eurofighter’s Am Söldnermoos 17, 85399 Hallbergmoos [email protected] ine Eurofighter’s place alongside a next generation fighter place alongside a next gen- in the future operating environment. Germany’s decision to replace eration fighter in the future Editorial Team Tony Garner its existing Tranche 1 aircraft battlespace.
    [Show full text]
  • French Aeronautical Players to Fly 100% Alternative Fuel on Single-Aisle Aircraft End of 2021
    French aeronautical players to fly 100% alternative fuel on single-aisle aircraft end of 2021 Toulouse, Paris, 10 June 2021- Airbus, Safran, Dassault Aviation, ONERA and Ministry of Transport are jointly launching an in-flight study, at the end of 2021, to analyse the compatibility of unblended sustainable aviation fuel (SAF) with single-aisle aircraft and commercial aircraft engine and fuel systems, as well as with helicopter engines. This flight will be made with the support of the “Plan de relance aéronautique” (the French government‘s aviation recovery plan) managed by Jean Baptiste Djebbari, French Transport Minister. Known as VOLCAN (VOL avec Carburants Alternatifs Nouveaux), this project is the first time that in-flight emissions will be measured using 100% SAF in a single-aisle aircraft. Airbus is responsible for characterising and analysing the impact of 100% SAF on-ground and in- flight emissions using an A320neo test aircraft powered by a CFM LEAP-1A engine1. Safran will focus on compatibility studies related to the fuel system and engine adaptation for commercial and helicopter aircraft and their optimisation for various types of 100% SAF fuels. ONERA will support Airbus and Safran in analysing the compatibility of the fuel with aircraft systems and will be in charge of preparing, analysing and interpreting test results for the impact of 100% SAF on emissions and contrail formation. In addition, Dassault Aviation will contribute to the material and equipment compatibility studies and verify 100% SAF biocontamination susceptibility. The various SAFs used for the VOLCAN project will be provided by TotalEnergies. Moreover, this study will support efforts currently underway at Airbus and Safran to ensure the aviation sector is ready for the large-scale deployment and use of SAF as part of the wider initiative to decarbonise the industry.
    [Show full text]
  • Sustainable Aviation Fuels Road-Map
    SUSTAINABLE AVIATION FUELS ROAD-MAP Fueling the future of UK aviation sustainableaviation.co.uk Sustainable Aviation wishes to thank the following organisations for leading the work in producing this Road-Map: Sustainable Aviation (SA) believes the data forecasts and analysis of this report to be correct as at the date of publication. The opinions contained in this report, except where specifically attributed to, are those of SA, and based upon the information that was available to us at the time of publication. We are always pleased to receive updated information and opinions about any of the contents. All statements in this report (other than statements of historical facts) that address future market developments, government actions and events, may be deemed ‘forward-looking statements’. Although SA believes that the outcomes expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance: actual results or developments may differ materially, e.g. due to the emergence of new technologies and applications, changes to regulations, and unforeseen general economic, market or business conditions. CONTENTS EXECUTIVE SUMMARY INTRODUCTION 1.1 Addressing the sustainability challenge in aviation 1.2 The role of sustainable aviation fuels 1.3 The Sustainable Aviation Fuels Road-Map SUSTAINABLE AVIATION FUELS 2.1 Sustainability of sustainable aviation fuels 2.2 Sustainable aviation fuels types 2.3 Production and usage of sustainable aviation fuels to date THE FUTURE FOR SUSTAINABLE
    [Show full text]
  • REFERENCE DOCUMENT Including the Sustainable Development Report Contents
    2015 REFERENCE DOCUMENT Including the Sustainable Development Report Contents Key Figures 2 1 Management Report 9 4 Financial statements 199 History of the Air Liquide Group 10 Consolidated fi nancial statements 201 Activities and risk factors 15 Statutory accounts of the parent company 275 2015 Performance 32 Investment cycle and fi nancing strategy 45 Innovation 53 Strategy and outlook 62 5 Annual General Meeting 2016 297 Board of Directors’ Report on the resolutions presented to the 2016 Combined Shareholders’ 2 2015 Corporate Social Responsibility Meeting 298 and Sustainable Development Report 65 Resolutions presented for the approval of the Combined Shareholders’ Meeting – Introduction 66 May 12, 2016 307 Our 2015 Social and Environmental Contribution 67 Statutory Auditors’ Reports 327 Environmental, social and governance (ESG) report 69 Reporting methodology 113 Independent verifi er’s report 115 Appendix 118 6 Additional information 339 Share capital 340 General information 346 3 Corporate governance 119 Trade payables 356 Factors that may have an impact in the event Management and control 120 of a takeover bid 357 Report from the Chairman of the Board of Directors 123 Person responsible for the Reference Document 359 Remuneration of the Executive Offi cers and Directors Cross-reference table for the Reference Document 360 of L’Air Liquide S.A. 147 Cross-reference table for the Annual Financial Report 364 Statutory Auditors’ Report 174 Cross-reference table for the Management Report 365 Transactions involving Company shares performed
    [Show full text]
  • Euronext Single Stock Dividend Futures: the Widest Choice of Contracts
    DIVIDEND DERIVATIVES: PLAY THE DIVIDEND FIELD WITH EURONEXT EURONEXT SINGLE STOCK DIVIDEND FUTURES: THE WIDEST CHOICE OF CONTRACTS September 2019 EURONEXT SSDFS: THE WIDEST CHOICE OF CONTRACTS 1st Dividend Exchange by number of contracts Number of contracts per country of underlying Number Number of SSDFs Underlyings ▪ Euronext began developing the range in of SSDFs only on Euronext Italy 24 11 January 2015 and regularly issues contracts Germany 27 0 to satisfy the needs of end-users Netherlands 23 9 ▪ We have nearly 300 SSDF contracts tradable Belgium 15 14 with the most diversified underlyings from Portugal 3 3 France 47 7 across Europe and the USA. Ireland 1 0 ▪ Investors can access dividend contracts on UK 36 10 new underlyings, as a total of 117 SSDFs are Spain 22 10 only available at Euronext exclusively. USA 57 36 Finland 7 2 Sweden 13 12 Norway 2 2 Switzerland 18 0 Austria 1 1 │ 2 INTRODUCTION OF SEMI-ANNUAL MATURITIES Euronext introduced semi-annual maturities on a range of Single Stock Dividend Futures listed on the Paris Derivatives Market, which offer new trading opportunities to market participants by helping them target dividend distributions more accurately on most traded names (see below). For these underlyings, the maturities available are 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months. UNDERLYING ISIN CODE TRADING SYMBOL 1 Sanofi FR0000120578 SA8 2 BNP Paribas FR0000131104 BN8 3 AXA FR0000120628 CS8 4 Air Liquide FR0000120073 AI8 5 Orange SA FR0000133308 FT8 6 Vinci SA FR0000133308 DG8 7 LVMH FR0000121014 MC8 8 ENGIE
    [Show full text]
  • Misinterpretation of Time-To-First Event Curves Can Lead to Inappropriate Treatment
    AGORA | CORRESPONDENCE Misinterpretation of time-to-first event curves can lead to inappropriate treatment To the Editor: Great care should be taken when assessing the consistency of treatment effect over time based on a survival curve plot, and even more so when a treatment affects a repeating event end-point, such as exacerbations, rather than an event that can occur only once, like death. In their recent editorial in the European Respiratory Journal,SUISSA and ARIEL [1] make the assertation that survival functions plotted from Kaplan–Meier estimates from figure 1b in the IMPACT study [2] “clearly show that the difference in the rate of exacerbation between LAMA/LABA/ICS and LAMA/LABA over follow-up is due to the first month’s surge, with practically no differences in the subsequent rates between the two groups”. However, this statement is based on a misunderstanding of the survival analyses presented. The events plotted on the figure are the first moderate or severe COPD exacerbations experienced by a patient in the IMPACT study. The statements made by SUISSA and ARIEL [1] about exacerbation rates refer to the rate of first exacerbations only, and not to the rate of all exacerbations during the study. Their conclusion that the rates of first exacerbations, and ratio between those rates changes over time is correct. However, this is entirely in line with statistical theory for repeated events with overall constant rates. It cannot be used to support any conclusion that the difference in the rate of exacerbation is due to a “first month’s surge”. The “digitised” curve of first events behaves entirely consistently with constant rate events.
    [Show full text]
  • Letter to Shareholders April 2021
    LETTER TO SHAREHOLDERS APRIL 2021 P. 2 — RESULTS P. 4 — COVID-19 P. 6 — CMD21 P. 8 — SHAREHOLDER INFORMATION RESULTS MESSAGE FROM FULL-YEAR 2020 THE CHAIRMAN RESULTS Business net Company sales1 income1 €36,041m €7,347m +3.3% (-0.2%) +9.6% (+4.2%) Serge Weinberg, Chairman of the Board of Directors Business EPS 1 , 2 2020 dividend3 Dear shareholders, Summarizing 2020 in a few words is difficult. The progress Sanofi has €5,86 €3.20 made in this first year of execution of the new strategy presented in +9.2% (+3.9%) per share December 2019 is very real. Our Research and Development pipeline is improving and the global business units are refocusing on their core activities. More than half of the cost savings achieved due to our collective efforts to be smarter in how we spend, has been reinvested in science. We strengthened our positioning in therapeutic areas through several acquisitions by adding pipeline projects where we already have a promising future. This would not have been possible without the support of all employees to the ‘Play to Win’ strategy. INTERVIEW WITH THE CHIEF Since the start of the health crisis, all our industrial sites have remained operational to maintain the continuous production of essential EXECUTIVE OFFICER medicines for patients. We have initiated two vaccine projects against COVID-19: for the most advanced of them1, the objective is to obtain approval of the health authorities in the fourth quarter of 2021 and first doses of the vaccine available for people worldwide to be ready. In the meantime, we are committed to helping some of our competitors whose vaccines have already been approved by participating in the manufacturing of millions of additional doses.
    [Show full text]